Teva Pharmaceutical Industries Limited TEVA
At closeNov 12, 2026, 7:51 PM EST
After hours · Nov 12, 7:51 PM ET
- YTD
- +39.86%
- 1 year
- +68.99%
- Market cap
- 50.93B
- Revenue (ttm)
- 17.23B
- Profit margin
- 2.94%
- EPS (ttm)
- 0.43
- Shares out
- 1.17B
- P/E ratio
- 101.51
- Forward P/E
- 13.96
- YTD return
- +39.86%
- 1-year return
- +68.99%
- Volume
- 9.25M
- Avg volume
- 5.98M
- Open
- 43.52
- Previous close
- 43.24
- Day's range
- 43.19 – 44.31
- 52-week range
- 24.01 – 44.31
- Beta
- 0.84
- Analysts
- Buy
- Price target
- 49.44 (+13.3%)
- Earnings date
- Jan 27, 2027
5D +1.88 (+4.50%)
Key statistics
- Enterprise value
- 63.37B
- PEG ratio
- 0.71
- Price / sales
- 2.96
- Price / book
- 6.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -1.90%
- Free cash flow
- 1.49B
- Total cash
- 4.08B
- Total debt
- 17.00B
- Return on equity
- 6.65%
- Short % of float
- 2.39%
- 50-day average
- 39.90
- 200-day average
- 34.99
Analyst view
Consensus: buy
- Target (low)
- 42.12
- Target (mean)
- 49.44
- Target (high)
- 57.00
- Strong buy4
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Jan 27, 2027
Expected Jan 27, 2027. Consensus EPS estimate 0.67005.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 27, 2027 | Dec 30, 2026 | 0.70 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | 0.72 | 0.86 | +0.14 | +19.44% |
| Jul 29, 2026 | Jun 30, 2026 | 0.08 | 0.02 | -0.06 | -75.00% |
| Apr 29, 2026 | Mar 31, 2026 | 0.50 | 0.53 | +0.03 | +6.00% |
| Jan 28, 2026 | Dec 31, 2025 | 0.65 | 0.96 | +0.31 | +47.69% |
| Nov 5, 2025 | Sep 30, 2025 | 0.68 | 0.78 | +0.10 | +14.71% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2026 | Piper Sandler | main | Overweight | Overweight |
| Nov 5, 2026 | Leerink Partners | main | Outperform | Outperform |
| Nov 4, 2026 | TD Cowen | main | Buy | Buy |
| Nov 4, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 2, 2026 | HC Wainwright & Co. | init | — | Buy |
| Oct 15, 2026 | Barclays | main | Overweight | Overweight |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- tevapharm.com
News
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56 
Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030 
Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030 
Teva Pharma Unveils Long-Term Growth Strategy, Targets $6B-$7B In Innovative Medicines Revenue By 2030 
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030 
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now? 
What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call 
Leerink Partners Maintains Outperform on Teva Pharmaceutical Indus, Raises Price Target to $52 
TD Cowen Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $57 
MindWalk Holdings Inks Agreement With Teva Pharmaceuticals Australia To Deploy ReefIQ
Your note
Sign in to keep a note on TEVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARER SOL J | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 448,011 |
| CRANE ROSEMARY A | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 127,739 |
| ELSTEIN AMIR | Director | Conversion of Exercise of derivative security | Jun 4, 2026 | 2,118,460 |
| FOX CHRISTINE | Officer | Sale | Mar 3, 2026 | 75,010 |
| FRANCIS RICHARD D | Chief Executive Officer | Sale | Jun 4, 2026 | 1,177,530 |
| HUGHES ERIC A | Officer | Sale | Aug 2, 2026 | 134,877 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.48% | 63,894,301 | 2.79B | Jun 29, 2026 |
| Phoenix Financial Ltd. | 3.65% | 42,625,947 | 1.86B | Sep 29, 2026 |
| WCM Investment Management, LLC | 3.62% | 42,253,473 | 1.84B | Sep 29, 2026 |
| Clal Insurance Enterprises Holdings Ltd | 3.48% | 40,596,506 | 1.77B | Jun 29, 2026 |
| Menora Mivtachim Holdings Ltd. | 3.42% | 39,854,383 | 1.74B | Jun 29, 2026 |
| Migdal Insurance & Financial Holdings Ltd. | 3.38% | 39,422,212 | 1.72B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | 1.46% | 17,083,534 | 745.70M | Jul 30, 2026 |
| INVESTMENT MANAGERS SERIES TRUST-WCM Focused International Growth Fund | 1.10% | 12,781,190 | 557.90M | Sep 29, 2026 |
| New Economy Fund | 1.06% | 12,327,600 | 538.10M | Sep 29, 2026 |
| VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund | 0.97% | 11,344,396 | 495.18M | Jun 29, 2026 |
| iShares Trust-iShares Core MSCI EAFE ETF | 0.76% | 8,854,390 | 386.49M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity Intl Fd. | 0.42% | 4,911,445 | 214.38M | Sep 29, 2026 |